Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?—A Comprehensive …
J Garnier, O Turrini, AS Chretien, D Olive - Journal of clinical medicine, 2022 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) remains a major killer and is a challenging
clinical research issue with abysmal survival due to unsatisfactory therapeutic efficacy. Two …
clinical research issue with abysmal survival due to unsatisfactory therapeutic efficacy. Two …
Use of Diagnostic Laparoscopy and Peritoneal Washings for Pancreatic Cancer
SM Ruff, S Tsai - Surgical Clinics, 2024 - surgical.theclinics.com
Pancreatic adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis.
Despite concerted research efforts, 5 year survival is still only 12% to 15%. 1 The …
Despite concerted research efforts, 5 year survival is still only 12% to 15%. 1 The …
[HTML][HTML] MiR-374b-5p inhibits KDM5B-induced epithelial-mesenchymal transition in pancreatic cancer
X Zhao, X Zhang, X Zhang, T Jiang, J Zhai… - American Journal of …, 2021 - ncbi.nlm.nih.gov
Micro (mi) RNAs play a critical regulatory role in the progression and metastasis of
pancreatic cancer (PC). In this study, we aimed to reveal the mechanisms of miR-374b-5p in …
pancreatic cancer (PC). In this study, we aimed to reveal the mechanisms of miR-374b-5p in …
Effect of the preoperative prognostic nutritional index on the long-term prognosis in patients with borderline resectable pancreatic cancer after …
JC Huang, B Pan, T Jiang, XX Zhang, SC Lyu… - Frontiers in …, 2023 - frontiersin.org
Background The preoperative prognostic nutritional index (PNI) is an indicator of systemic
immune-nutritional condition and is a well-known prognostic biomarker in cancer patients …
immune-nutritional condition and is a well-known prognostic biomarker in cancer patients …
Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer
HY Chon, HS Lee, YN Sung, YK Tae, CH Park… - Scientific Reports, 2024 - nature.com
To identify risk factors and biomarker for early recurrence in patients diagnosed with
pancreatic cancer who undergo curative resection. Early recurrence after curative resection …
pancreatic cancer who undergo curative resection. Early recurrence after curative resection …
Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean–Japanese joint cohort and the SEER database
W Kwon, JS Heo, IW Han, CM Kang… - Journal of Hepato …, 2023 - Wiley Online Library
Abstract Background/Purpose Little is known about the features of T1 pancreatic ductal
adenocarcinoma (PDAC) and its definition in the eighth edition of the American Joint …
adenocarcinoma (PDAC) and its definition in the eighth edition of the American Joint …
Response to neoadjuvant therapy and prognosis in patients with resectable pancreatic cancer: a propensity score matching analysis
MS Yoon, HS Lee, CM Kang, WJ Lee, J Keum… - Gut and …, 2021 - pmc.ncbi.nlm.nih.gov
Background/Aims Controversy regarding the effectiveness of neoadjuvant therapy for
resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify …
resectable pancreatic ductal adenocarcinoma (PDAC) still exists. Here, we aimed to identify …
[HTML][HTML] A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration
J Ge, L Li, Z Ma, B Jiang, C Yuan, H Wang, Y Peng… - Gland …, 2021 - ncbi.nlm.nih.gov
Background Surgical resection is the only potentially curative treatment for pancreatic ductal
adenocarcinoma (PDAC). However, most of patients lose the chance of surgery due to the …
adenocarcinoma (PDAC). However, most of patients lose the chance of surgery due to the …
Identifying optimal candidates for tumor resection among borderline and locally advanced pancreatic cancer: A population-based predictive model
Z Lu, W Shao, X Shi, T Tan, C Xing, Z Li, J Xu, H Cui… - Pancreatology, 2022 - Elsevier
Background Whether patients with borderline resectable and locally advanced pancreatic
cancer (BR/LAPC) benefit from resection of the primary cancer is controversial. We …
cancer (BR/LAPC) benefit from resection of the primary cancer is controversial. We …
The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative …
M Walma, L Maggino, FJ Smits, AS Borggreve… - Journal of clinical …, 2024 - mdpi.com
Occult metastases are detected in 10–15% of patients during exploratory laparotomy for
pancreatic cancer. This study developed and externally validated a model to predict occult …
pancreatic cancer. This study developed and externally validated a model to predict occult …